Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma

mAbs

Volumn 1, Issue 1, 2009, Pages 31-40

  Alinari, Lapo ^a   White, Valerie L ^a   Earl, Christian T ^a   Ryan, Timothy P ^a   Johnston, Jeffrey S ^a   Dalton, James T ^a   Ferketich, Amy K ^a   Lai, Raymond ^b   Lucas, David M ^a   Porcu, Pierluigi ^a   Blum, Kristie A ^a   Byrd, John C ^a   Baiocchi, Robert A ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Apoptosis; CD20; Mantle cell lymphoma; Proteasome inhibition; Survival and death pathways

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; BORTEZOMIB; CASPASE; CASPASE 24; CASPASE 3; CASPASE 48; CASPASE 8; CASPASE 9; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN MCL 1; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IMMUNOBLOTTING; MANTLE CELL LYMPHOMA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BORONIC ACIDS; CELL LINE, TUMOR; CELL SURVIVAL; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; LYMPHOMA, MANTLE-CELL; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; TUMOR CELLS, CULTURED;

EID: 77953665404     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.1.1.7472     Document Type: Article

References (53)

1. The non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997; 89:3909-3918
2. Swerdlow SH, Berger F, Isaacson PI, Muller-Hermelink HK, Nathwani BN, Piris MA et al. World Health Organization Classification of Tumors: Pathology and Genetics of tumors of Hematopoietic and Lymphoid Tissues. IARC Press 2001; 168-170
3. Fisher RI, Dahlberg S, Nathwani B, Banks PM, Miller TP, Grogan TM. A clinical analysis of two indolent lymphomentities: mantle cell lymphoma and marginal zone lymphoma (including mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group Study. Blood 1995; 85:1075-1082
4. Bosch F, Lopez-Guillermo A, Campo E, Ribera JM, Conde E, Piris MA, Vallespi T, et al. Mantle cell lymphoma: presenting features, response to therapy and prognostic factors. Cancer 1998; 82:567-575 (Pubitemid 28112997)
5. Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol 1999; 36:115-127
6. Teodorovic I, Pittaluga S, Kluin-Nelemans JC, Meerwaldt JH, Hagenbeek A, van Glabbeke M, et al. Efficacy of four different regimens in 64 mantle cell lymphoma cases: Clinicopathologic comparison with 98 other non-Hodgkin's lymphoma subtypes-European Organization for the Research and treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1995; 13:2819-2826
7. Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M, et al. HyperCVAD and high-dosemethotrexate/cytarabine followed by stem cell transplantation: an active regimen for aggressive mantle cell lymphoma. J Clin Oncol 1998; 16:3803-3809 (Pubitemid 29001533)
8. Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23:1984-1992.
9. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 2004; 22:304-311 (Pubitemid 38725184)
10. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Bortezomib: proteasome inhibition as an effective anticancer therapy. Ann Rev Med 2006; 57:33-47. (Pubitemid 43261977)
11. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. The proteasome as a target for cancer therapy. Clin Cancer Res 2003; 9:6316-6325
12. Voorhees PM, Orlowski RZ. The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol 2006; 46:189-213.
13. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005; 23:630-639 (Pubitemid 46224241)
14. Caravita T, de Fabritiis P, Palumbo A, Amadori S, Boccadoro M. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. Nat Clin Pract Oncol 2006; 3:374-387 (Pubitemid 44027292)
15. Cavo M. Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia 2006; 20:1341-1352 (Pubitemid 44084044)
16. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:667-675 (Pubitemid 46224166)
17. Mori N, Fujii M, Ikeda S, Yamada Y, Tomonaga M, Ballard DW, Yamamoto N. Constitutive activation of NFkappaB in primary adult T-cell leukemia cells. Blood 1999; 93:2360-2368 (Pubitemid 29153640)
18. Wang B, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factorkappaB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999; 5:119-127 (Pubitemid 29045184)
19. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr. Constitutive activation of NFkappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997; 17:3629-3636 (Pubitemid 27281838)
20. Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997; 100:2961-2969 (Pubitemid 28022832)
21. Pham L, Tamayo A, Yoshimura L, Lo P, Ford RJ. Inhibition of Constitutive NFκB Activation in Mantle Cell Lymphoma B Cells Leads to Induction of Cell Cycle Arrest and Apoptosis. J Immunol 2003; 171:88-95. (Pubitemid 36745276)
22. Lopes UG, Erhardt P, Yao R, Cooper GM. p53-dependent induction of apoptosis by proteasome inhibitors. J of Biol Chemistry 1997; 272:12893-12896 (Pubitemid 27216701)
23. Gregory MA, Hann SR. c-myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol 2000; 20:2423-2435 (Pubitemid 30152050)
24. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin dependent kinase inhibitor p27. Science 1995; 269:682-685
25. Chiarle R, Budel LM, Skolnik J, Frizzera G, Chilosi M, Corato A, et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with decreased overall survival in mantle cell lymphoma. Blood 2000; 95:619-626 (Pubitemid 30041678)
26. O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23:676-684 (Pubitemid 46237441)
27. Wang M, Han XH, Zhang L, Yang J, Qian JF, Shi YK, et al. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia 2008; 22:179-185
28. Ishiyama K, Takami A, Okumura H, Ozaki J, Shimadoi S, Yamanaka S et al. Complete and durable remission of refractory mantle cell lymphoma with repeated rituximab monotherapy. Int J Hematol 2005; 4:319-322 (Pubitemid 41708638)
29. Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, Solal-Celigny P, Ghielmini M, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle cell lymphoma, immunocytoma and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18:317-324 (Pubitemid 30056420)
30. Ghielmini M, Schmitz SF, Cogliatti S, Bertoni F, Waltzer U, Fey MF, et al. Effect of singleagent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005; 23:705-711 (Pubitemid 46224169)
31. Foran JM, Cunningham D, Coiffier B, Solal-Celigny P, Reyes F, Ghielmini M, et al. Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol 2000; 11:117-121 (Pubitemid 30111879)
32. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998; 91:1644-1652 (Pubitemid 28110329)
33. Jazirehi AR, Gan XH, de Vos S, Emmanouilides C, Bonavida B. Rituximab (anti-CD20) selectively modifies bcl-xl and Apaf-1 expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 2003; 2:1183-1193
34. Jazirehi AR, Huerta-Yepez S, Cheng G. Bonavida G. Rituximab (Chimeric Anti-CD20 monoclonal Antibody) Inhibits the Constitutive Nuclear FactorκB Signaling Pathway in Non-Hodgkin's Lymphoma B-Cell Lines: Role in Sensitization to Chemotherapeutic Drug- Induced Apoptosis. Cancer Res 2005; 65:264-276 (Pubitemid 40070818)
35. Lai R, McDonnell TJ, O'Connor SL, Medeiros LJ, Oudat R, Keating M, et al. Establishment and characterization of a new mantle cell lymphoma cell line, Mino. Leuk Res 2002; 26:849-855 (Pubitemid 34778500)
36. Jeon HJ, Kim CW, Yashino T. Establishment and characterization of a mantle cell lymphoma cell line. Br J Haematol 1998; 102:1323-1326 (Pubitemid 28435219)
37. Amin HM, McDonnell TJ, Medeiros LJ, Rassidakis GZ, Leventaki V, O'Connor SL, et al. Characterization of 4 Mantle Cell Lymphoma Cell Lines. Arch Pathol Lab Med 2003; 127:424-431
38. Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. Proteasome inhibition measurements: clinical application. Clin Chem 2000; 46:673-683 (Pubitemid 30318423)
39. Roychowdhury S, Baiocchi RA, Vourganti S, Bhatt D, Blaser BW, Freud AG, et al. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder. J Natl Cancer Inst 2004; 96:1447-1457 (Pubitemid 39429669)
40. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004; 22:2108-2121 (Pubitemid 41095144)
41. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20:4420-4427 (Pubitemid 35334752)
42. Hamilton AL, Eder JP, Pavlick AC, Clark JW, Liebes L, Garcia-Carbonero R, et al. Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol 2005; 23:6107-6116 (Pubitemid 46300228)
43. Bellosillo B, Villamor N, López-Guillermo A, Marcé S, Esteve J, Campo E, et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood 2001; 98:2771-2777
44. Herrant M, Jacquel A, Marchetti S, Belhacène N, Colosetti P, Luciano F, et al. Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene 2004; 23:7863-7873 (Pubitemid 39457036)
45. Martinez N, Camacho FI, Algara P, Rodríguez A, Dopazo A, Ruíz-Ballesteros E, et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res 2003; 63:8226-8232 (Pubitemid 37549472)
46. Rudelius M, Pittaluga S, Nishizuka S, Pham TH, Fend F, Jaffe ES, et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 2006; 108:1668-1676 (Pubitemid 44316136)
47. Bonavida G. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007; 26:3629-3636 (Pubitemid 46842700)
48. Wang CY, Guttridge DC, Mayo MW, Baldwin AS Jr. NFkappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999; 19:5923-5929 (Pubitemid 29399297)
49. 1-to-S-phase transition. Mol Cell Biol 1999; 19:2690-2698
50. Bogner C, Ringshausen I, Schneller F, Fend F, Quintanilla-Martinez L, Häcker G, et al. Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells. Br J Haematol 2003; 122:260-268 (Pubitemid 36859612)
51. Pérez-Galán P, Roué G, Villamor N, Villamor N, Montserrat E, Campo E et al. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006; 107:257-264 (Pubitemid 43053550)
52. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. Modulation of NFkappaB activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 2000; 164: 2200-2206 (Pubitemid 30108780)
53. Nencioni A, Hua F, Dillon CP, Yokoo R, Scheiermann C, Cardone MH, et al. Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. Blood 2005; 105: 3255-3262 (Pubitemid 40504347)